Pfizer, BioNTech To Seek Emergency Approval For Covid-19 Vaccine On Friday

Author image

Robert Hart   Forbes U.S. Staff

Pfizer, BioNTech To Seek Emergency Approval For Covid-19 Vaccine On Friday

Photo: Pfizer Inc. Twitter 

Pfizer and BioNTech will apply for emergency regulatory approval in the U.S. Friday for their Covid-19 vaccine—as the companies announced they would earlier this week—days after a clinical trial showed the vaccine to be 95% effective at preventing the disease. 

KEY FACTS

- This is the first time a company has sought regulatory approval for a Covid-19 vaccine which, if approved, will mark the first time a vaccine built using mRNA technology has made it to market.

- The application comes days after the companies announced a 95% efficacy rate for the vaccine based on an extensive Phase 3 clinical trial involving more than 40,000 volunteers. 

- The results show the highest efficacy rate of any late-stage Covid-19 vaccine in development — far higher than the 50% U.S. regulators had been willing to accept — and the companies report “no serious safety concerns” with the vaccine. 

 

Author image

Robert Hart   Forbes U.S. Staff

I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge.